The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Otitis Media-Related Antibiotic Use Among Young Children in Tennessee, USA

Hannah Griffith; Andrew D Wiese; Edward F Mitchel Jr; Carlos G Grijalva

doi:10.1093/ofid/ofac019

The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Otitis Media-Related Antibiotic Use Among Young Children in Tennessee, USA

Open Forum Infect Dis. 2022 Feb 14;9(3):ofac019. doi: 10.1093/ofid/ofac019. eCollection 2022 Mar.

Authors

Hannah Griffith¹, Andrew D Wiese¹, Edward F Mitchel Jr¹, Carlos G Grijalva^{1

2}

Affiliations

¹ Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
² Veterans Affairs Tennessee Valley Health Care System, Nashville, Tennessee, USA.

Abstract

Otitis media (OM) is a leading cause of pediatric antibiotic use. Introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) led to reductions in OM among US children, though its impact on OM-related antibiotic use remains unclear. Among 499 683 Tennessee children <2 years of age, the OM-related antibiotic fill rate was stable after PCV13 introduction.

Keywords: antibiotic use; otitis media; pneumococcal conjugate vaccines.

Abstract

Grants and funding